English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, December 8, 2017
エーザイ、エリブリンとペムブロリズマブ併用による転移性トリプルネガティブ乳がんを対象とした臨床第Ib/II相試験のアップデート解析について発表
Eisai: Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Combination Regimen
Wednesday, December 6, 2017
Eisai Submits Application for Expanded Indication Covering Hepatocellular Carcinoma for Anticancer Agent Lenvima in Taiwan
エーザイ、抗がん剤「レンビマ(R)」が台湾において肝細胞がんに係る適応拡大を申請
Thursday, November 30, 2017
Eisai's Resubmitted NDA for Anticancer Agent Halaven Accepted in China
Wednesday, November 29, 2017
エーザイ、中国における抗がん剤「ハラヴェン(R)」の新薬承認の再申請が受理
Friday, November 24, 2017
Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting
エーザイ、第71回米国てんかん学会議にてペランパネルおよびルフィナミドに関する最新データを発表
Monday, November 20, 2017
Eisai Receives IT Business Award for Medication Administration Support Device e-OKUSURI-SAN
Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575